Latest News

UCB psoriasis drug beats J&J’s second top-selling product in Phase III study

Psoriasis Diagnosis, Medical Concept. Composition of Medicaments

Results of the BE VIVID study showed that UCB’s bimekizumab showed a statistically significant improvement in skin clearance compared with J&J’s Stelara and placebo.

Source link

Related posts

Tips For Better Dental Flossing


ImmunogenX Completes CypCel Trial for Celiac Disease


Reprogramming cells to control HIV infection


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy